Vorozole (Rivizor(TM)): An active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure

1998-03-09

Anti-Cancer Drugs , Volume 9 - Issue 1 p. 29- 35

Additional Metadata
Keywords	Aromatase, Breast cancer, Metastatic, Phase II, Postmenopausal, Vorozole
Persistent URL	doi.org/10.1097/00001813-199801000-00003, hdl.handle.net/1765/63578
Journal	Anti-Cancer Drugs
Organisation	Department of Medical Oncology
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Paridaens, R., Roy, J., Nooij, M. A., Klijn, J., Houston, S., Beex, L., Vinholes, J., Tomiak, E., van Vreckem, A., Langenaeken, C., van Glabbeke, M.& Piccart, M. (1998). Vorozole (Rivizor(TM)): An active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Anti-Cancer Drugs, 9(1), 29–35.https://doi.org/10.1097/00001813-199801000-00003

Publication